Top Medical News
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Stephen Padilla, an hour ago
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Hidradenitis suppurativa: Treatment by specialist, with biologics dictate satisfaction
4 days ago
Among patients with hidradenitis suppurativa, treatment satisfaction is high for those who are treated by a dermatologist and receive a biologic medication, a study has found.
Topical isotretinoin eases symptoms in recessive congenital ichthyosis
6 days ago
A phase IIb trial has found that TMB-001, a novel topical isotretinoin ointment, can safely improve symptoms of hyperkeratosis and widespread scaling in patients with X-linked recessive or autosomal recessive congenital ichthyosis (CI).
FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides
Jairia Dela Cruz, 03 Aug 2022
Photodynamic therapy using topically applied hypericin 0.25% is effective against early-stage patch and plaque lesions in patients with mycosis fungoides−cutaneous T-cell lymphoma, while having a favourable safety profile, as shown in the phase III FLASH trial.
Antenatal vitamin D supplementation may curb risk of infant eczema
Jairia Dela Cruz, 01 Aug 2022
Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).
Abrocitinib safe, effective in moderate-to-severe atopic dermatitis after dupilumab use
Stephen Padilla, 26 Jul 2022
Treatment with abrocitinib is both safe and effective in patients with moderate-to-severe atopic dermatitis (AD), regardless of prior dupilumab response status, a study has shown.
Weekly hypofractionated radiotherapy safe, effective in elderly cSCC patients
26 Jul 2022
A weekly treatment schedule of hypofractionated radiotherapy appears to yield good response rate in elderly patients with cutaneous squamous cell carcinoma (cSCC), while having minimal side effects, a study has shown.
Special Reports
Product Highlight - Canespro
15 Jun 2022
Bifonazole Anti-Fungal Cream 1% w/w
Product Highlight - RELIZEMA
16 Jun 2021
Furfuryl Palmitate
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Cochrane review confirms Atopiclair efficacy in eczema
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
Conference Reports
Baricitinib may improve hair regrowth in alopecia areata
Roshini Claire Anthony, 02 May 2022

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.

Dupilumab stops the itch, clears skin lesions in phase III trial
Elvira Manzano, 29 Apr 2022
The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.
Roflumilast cream reduces psoriasis severity
Elaine Soliven, 27 Apr 2022
Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.
Cutaneous reactions after 1st COVID-19 vaccine dose no reason to forgo 2nd dose
Elvira Manzano, 27 Apr 2022
Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.
Ruxolitinib cream improves repigmentation in patients with vitiligo
Elaine Soliven, 09 Nov 2021
The application of ruxolitinib cream led to significant improvements in facial and total body repigmentation among adolescents and adults with vitiligo, according to two phase III studies presented at EADV 2021.
Ritlecitinib prevents hair loss in patchy baldness
Pearl Toh, 22 Oct 2021
The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.
Elaine Soliven, 22 Oct 2021
Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.
Product Highlights
CME Modules